BELITE BIO INC.SP.ADR/1 Depository Receipt · US07782B1044 · BLTE · A3DKYL (XNCM) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of BELITE BIO INC.SP.ADR/1

Analyst Grade Summary

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

No Price

01.05.2026 20:00

Current Prices from BELITE BIO INC.SP.ADR/1

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	BLTE	USD	01.05.2026 20:00	154,85 USD	-4,31 USD -2,71 %
IEX	BLTE	USD	01.05.2026 19:59	154,85 USD	-4,31 USD -2,71 %
Düsseldorf	BELITE44.DUSB	EUR	30.04.2026 14:00	132,00 EUR	-
Quotrix	BELITE44.DUSD	EUR	30.04.2026 05:27	133,00 EUR	-

ESG Risk Rating

B Good

Share Float & Liquidity

Free Float 46,30 %

Shares Float 18,5 M

Shares Outstanding 39,97 M

Company Profile for BELITE BIO INC.SP.ADR/1 Depository Receipt

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.